Theralase Grants Stock Options - WAFF-TV: News, Weather and Sports for Huntsville, AL

Theralase Grants Stock Options

Posted: Updated:

Toronto, Ontario / ACCESSWIRE / July 16, 2014 / Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTC Link(R)) announced effective today that it has granted an aggregate of 1,800,000 stock options to directors and officers at an exercise price of $CAN 0.50 vesting over three years and expiring five years from date of issue.

These stock options were granted to directors and officers in compliance with the Company’s 2004 Stock Option Plan approved by the shareholders of the Corporation at the Annual General and Special Meeting held on November 29, 2013.

These stock options were granted as a means of rewarding directors and officers for future services to be provided to the Corporation, including: the launch of the patented TLC-2000 biofeedback therapeutic laser system in 4Q2014 and the commencement of FDA Phase I / IIa human clinical studies in bladder cancer for its patented and patent pending anti-cancer Photo Dynamic Compound (PDC) technology in 1Q2015.

About Theralase Technologies Inc.

Founded in 1994, Theralase Technologies Inc. (“Theralase”) (TSXV: TLT) (TLTFF: OTC Link(R)) designs, manufactures and markets patented super-pulsed laser technology which is used for the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing. Theralase has sold over 800 systems in Canada and over 400 systems in the US and international markets to licensed healthcare practitioners such as: medical doctors, chiropractors, physical therapists and athletic therapists. Theralase has been so successful in healing nerve, muscle and joint conditions in clinical practice that Theralase’s scientists are now investigating the application of its lasers in the destruction of cancer using specially designed molecules called Photo Dynamic Compounds (PDCs) which localize to the DNA of cancer cells and then, when activated by light, destroy the cancer cells.

Additional information is available at www.theralase.com and www.sedar.com .

This press release contains forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

Roger Dumoulin-White

President & CEO, Theralase Technologies Inc.

1.866.THE.LASE (843-5273) ext. 225

416.699.LASE (5273) ext. 225

rwhite@theralase.com

www.theralase.com 

SOURCE: Theralase Technologies Inc.   

ReleaseID: 417888

Powered by WorldNow

1414 North Memorial Parkway
Huntsville, AL 35801
256-533-4848

WAFF Is a Proud Member
of the Raycom Family of Stations


FCC Public File
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and WAFF. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.